

Original Article

A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis mediated through FoxP3⁺ CD8 T-cells[†]

Zachary S. Buchwald¹, Chang Yang², Suman Nellore¹, Elena V. Shashkova¹, Jennifer L. Davis², Anna Cline¹, Je Ko¹, Deborah V. Novack², Richard DiPaolo¹ and Rajeev Aurora^{1*}

¹Department of Molecular Microbiology and Immunology,
Saint Louis University School of Medicine

²Division of Bone and Mineral Disease, Department of Medicine,
Washington University in St. Louis

*Corresponding Author:

Rajeev Aurora, PhD.

Molecular Microbiology and Immunology

1100 South Grand Boulevard, DRC 605

Saint Louis University School of Medicine

St. Louis, MO 63104 USA

Email: aurorar@slu.edu

Tel: +1 (314) 977-8891

Fax: +1 (314) 977-8717

Conflict Statement: The authors have declared that no conflict of interest exists.

[†]This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/jbmr.2472]

Additional Supporting Information may be found in the online version of this article.

Initial Date Submitted December 15, 2014; Date Revision Submitted January 15, 2015; Date Final Disposition Set January 30, 2015

Journal of Bone and Mineral Research
This article is protected by copyright. All rights reserved
DOI 10.1002/jbmr.2472

ABSTRACT

TNF α and IL-17 secreted by proinflammatory T-cells (T_{EFF}) promote bone erosion by activating osteoclasts. We previously demonstrated that in addition to bone resorption, osteoclasts act as antigen presenting cells to induce FoxP3 in CD8 T-cells (T_{REG}). The osteoclast-induced regulatory CD8 T-cells limit bone resorption in ovariectomized mice (a murine model of postmenopausal osteoporosis). Here we show that while low-dose RANKL maximally induces T_{REG}, via Notch signaling pathway, to limit bone resorption high-dose RANKL promotes bone resorption. *In vitro*, both TNF α and IL-17, cytokines that are abundant in ovariectomized animals, suppress T_{REG} induction by osteoclasts by repressing Notch ligand expression in osteoclasts but this effect can be counteracted by addition of RANKL. Ovariectomized mice treated with low-dose RANKL induced T_{REG} that suppressed bone resorption, decreased T_{EFF} levels and increased bone formation. High dose RANKL had the expected osteolytic effect. Low dose RANKL administration in ovariectomized mice lacking CD8 T-cells was also osteolytic, confirming that T_{REG} mediate this bone anabolic effect. Our results show that while RANKL directly stimulates osteoclasts to resorb bone, it also controls the osteoclasts' ability to induce regulatory T-cells, engaging an important negative feedback loop. In addition to the conceivable clinical relevance to treatment of osteoporosis, these observations have potential relevance to induction of tolerance and autoimmune diseases. This article is protected by copyright. All rights reserved

INTRODUCTION

Osteoimmunology is an emerging study of the crosstalk between the immune and skeletal systems. Osteoimmunology arose from the recognition that cytokines produced by lymphocytes can affect bone homeostasis (1). While much is known about the cytokines and mechanisms that lead to bone erosion by the proinflammatory cytokines (2-5), much less is known about the mechanisms that maintain or restore homeostasis (i.e. the healthy state). It is anticipated that there must be feedback loops in both the immune and skeletal systems that maintain and restore homeostasis after perturbations or changes to the system that arise due to pathologic (e.g. infections) and normal physiological processes (e.g. pregnancy).

The current study builds on previous work where we have identified a novel regulatory feedback loop between CD8 T-cells and osteoclasts (6-10). Specifically, osteoclasts induced the transcription factor Forkhead box protein 3 (FoxP3) in CD8 T-cells. FoxP3 is a master regulator of regulatory T-cells (11). While regulatory CD8⁺ T-cells, called T_{CREG}, have been documented in humans and mice (11-21) they have not been studied extensively, in part due to their low abundance (0.2 to 2% of CD8⁺ T-cells) in lymphoid organs. In comparison, the well-studied CD4⁺ regulatory T-cells, T_{REG}, comprise 5-12% of CD4⁺ T-cell in the spleen. T_{CREG} and T_{REG} have overlapping and distinct functions. Both cells express CD25 and the transcription factor FoxP3, a marker of regulatory T-cells (22-24). T_{REG} are critical for suppressing the aberrant activation of self-reactive T-cells (17) as depletion of T_{REG} or genetic ablation of FoxP3 in CD4 T-cells leads to multi-organ autoimmune syndrome (25-27). T_{CREG}, in contrast, ostensibly do not maintain global suppression of self-reactive T-cells (28), but have immune-suppressive activity (29). The two regulatory T-cells are activated differently: thymically and peripherally produced T_{REG} require restimulation through their T-cell receptor (TCR) by MHC class II to express their suppressive effector functions (30). The maturation of antigen presenting cells (APC) that express MHC class II needed for restimulation is tightly regulated (31,32). In contrast, T_{CREG} do not require restimulation (8). In any case, as all cells (except red blood cells) constitutively express MHC class I, any cell could potentially stimulate T_{CREG}, and therefore an overabundance of T_{CREG} may lead to immune suppression. A number of studies (33-35), including ours (8), have shown that T_{CREG} are rapidly induced (24 to 48 hours) locally in tissue from naïve CD8 T-cells; hence their steady state abundance is low in lymphoid tissue.

In particular, we have shown *in vitro* that osteoclasts, in addition to having a bone resorbing activity, also have an antigen presenting activity. Osteoclasts crosspresent

(extracellular) antigens and activate CD8 T-cells to induce FoxP3, CD25, interleukin (IL)-2, IL-6, IL-10 and interferon (IFN)- γ in the CD8 T-cells. The osteoclast-induced T_{REG} (OC-iT_{REG}) suppress bone resorption by osteoclasts to form a negative feedback loop. The suppression of bone resorption activity has been demonstrated *in vitro* (8) and in two different models of bone loss *in vivo* (10). Unlike the bone marrow T_{REG}, thymically produced T_{REG} do not efficiently suppress osteoclast activity (Buchwald and Aurora, unpublished observations). T_{REG} may also be induced in the tonsils (36,37) and elsewhere. Both the endogenous bone marrow T_{REG} and *ex vivo* generated OC-iT_{REG} suppressed bone resorption in mice in response to 1 mg/ml RANKL administration (10). Adoptively transferred OC-iT_{REG} also suppressed bone resorption by reducing the numbers of osteoclasts in ovariectomized mice (10). We have also shown that transfer of *ex vivo* generated OC-iT_{REG} are immunosuppressive *in vivo* because they decrease the levels of proinflammatory effector T-cells (T_{EFF}) in the bone marrow, which increase in ovariectomized animals, to levels found in sham operated mice (10). These results established that OC-iT_{REG} negatively regulate osteoclast activity and the immune system.

Homeostasis, the ability to maintain a stable set point in response to physiologic or environmental changes, is achieved through a number of regulatory motifs (38-41). One of these motifs, referred to as the reactive negative regulator ensures that responses to stimuli are of the appropriate intensity, duration and are subsequently terminated or resolved (9,42). For example, acute inflammation is an appropriate and healthy response to an infection or trauma that clears or dilutes the offending agent and activates repair mechanisms. Acute inflammation is a healthy response, as long as it is brief and intense enough to clear the infection and then resolves with minimal collateral damage. The failure of activation of the reactive regulatory motif can often lead to pathology. As T_{REG} represent an example of a reactive negative regulator, we believe a better understanding of this system can provide insights into how such regulation is lost during pathogenesis and/or used to maintain or restore homeostasis.

Here, we initiated our study to test the ability of osteoclasts to induce T_{REG} *in vivo*. We found that activation of osteoclasts is needed to induce T_{REG}, consistent with our expectation that T_{REG} are reactive negative regulators. However, these results beg the question: what defect(s) in the osteoclast—T_{REG} feedback system allows excess bone resorption in ovariectomized mice (and by inference in postmenopausal osteoporosis)? Our studies provide a surprising result that could not have been anticipated in the absence of knowledge of the feedback loop: that under some conditions RANKL leads to an increase in bone density.

MATERIALS AND METHODS:

Mice: C57BL/6J mice (model 000664) were purchased from Jackson Laboratory or used from in-house breeding colonies. Breeders of FoxP3^{eGFP} reporter (model 006772) and β 2M^{-/-} (model 002087) mice were purchased from Jackson Laboratory, and bred in-house for these experiments. OT-I Rag^{-/-} mice were purchased from Taconic. Breeders of OT-I Thy1.1 Rag^{-/-} mice were a gift of Dr. Ryan Teague (St. Louis University School of Medicine). All animals were maintained in the Department of Comparative Medicine, Saint Louis University School of Medicine in accordance with institutional and Public Health Service Guidelines. Saint Louis University School of Medicine Institutional Animal Care and Use Committee approved all procedures performed on mice (protocol numbers 2072 and 2184).

Ovariectomy: Bilateral ovariectomy was performed on 12-14 week old mice. Mice were anesthetized using 2.5% isoflurane to initiate anesthesia, and 1% for maintenance. The ovaries were accessed through a single incision in the skin, and exteriorized through muscle wall on each side. Each ovary was clamped using hemostat and removed by a single cut. Skin staples (3M) were used to close the skin incision. To minimize discomfort post-surgery, 0.025 mg/kg Buprenorphine was administered subcutaneously. Zoledronate (Selleck Chemicals) was administered at 30 μ g/kg via tail vein.

Adoptive transfer of T-cells: All T-cells were transferred via tail vein. For injections mice were restrained and 20x10⁶ T-cells, suspended in 100-150 μ l PBS were injected into the lateral vein.

Generation of OC: OC precursors were isolated as previously described (7,8). Briefly, the mice were sacrificed by CO₂ asphyxiation and the long bones harvested. One end cap of the bone was removed and the long bones were placed in a 0.7 ml microcentrifuge tube, pierced with a 22G needle at the bottom of the tube. The 0.7 ml tube was fitted inside a 1.5 ml microcentrifuge tube. The assembly was spun for 30 seconds at 16,000xg. The bone marrow cells were resuspended in α -minimum essential medium (α MEM, Invitrogen), and filtered through a 40- μ cell strainer. The cells were pelleted, resuspended and maintained in α MEM growth medium (α MEM supplemented with 10% heat-inactivated fetal bovine serum [Invitrogen]), penicillin-streptomycin-glutamine (Invitrogen) and recombinant murine M-CSF (Peprotech) at 20 ng/ml). OC were generated by addition of recombinant murine GST-RANKL (a gift of Prof. Steven Teitelbaum, Washington University in St. Louis) to a final concentration of 50 ng/ml. M-CSF and GST-RANKL were added every 48 to 72 h.

Isolation of T-cells: Single cell suspensions of spleens were prepared in PBS + 1% FBS by grinding with a sterile syringe plunger and dispersed by pipetting, then filtering through a 40 μ cell strainer. For co-culture experiments, splenic OT-I or WT CD8 T-cells were prepared by first enriching for T-cells using Pan-T-cell beads and further purified by negative selection using appropriate magnetic beads (Miltenyi). All bone marrow and splenic T-cells purified by positive selection were incubated for 30 m at 37° C to allow cells to allow dissociation or uptake of bound beads from cell surface. The resulting T-cells were routinely > 97% pure when stained with anti-CD3, anti-CD4 and anti-CD8 antibody.

Generation of OC-iT_{REG}: Day 4 OC cultured in 20 ng/ml M-CSF and 50 ng/ml GST-RANKL, were seeded at 5×10^5 cells/well in the presence of 5 μ M OVA (A-5503; Sigma-Aldrich) in 24-well tissue culture-treated plates (Corning). After 14–16 h of incubation, medium was removed and (adherent) cells were washed with pre-warmed medium. 2.5×10^5 freshly harvested splenic OT-I transgenic T cells purified by negative selection were added in 2 ml of complete T-cell media (RPMI, 10% Δ FBS, penicillin-streptomycin-glutamine, non-essential amino acids, sodium pyruvate, HEPES, and 55 μ M β -mercaptoethanol). Following 48 h co-culture, T-cell aliquots were removed and intracellular staining was performed to assess FoxP3 expression. The T_{REG} were then further expanded, in the absence of OC, by splitting cells 1:2 and culturing in 100 U/ml IL-2 containing T-cell media for an additional 48 h. For polyclonal T_{REG} generation, T-cells were purified from spleens of C57BL/6 mice and incubated with day 4 OC in the presence of 1 μ g/ml anti-CD3. Control T-cells were activated with plate bound anti-CD3 (1 μ g/ml) and anti-CD28 (2 μ g/ml; both from eBiosciences) for 48 hours; the activated T-cells were expanded further by splitting 1:2 and culturing for additional 48 hours in IL-2 (100 U/ml). 20×10^6 T_{REG} (in 200 μ l) were then injected by tail vein into 8-week-old OT-I mice.

PCR assessment of expression of CD200 and Notch ligands: Osteoclasts seeded on day 4 at 1.5×10^6 cells/ml were used in all experiments. RNA was isolated at time point described in Figure legends. 10 to 50 ng of RNA was used for first-strand cDNA synthesis in 50 μ L reaction per kit instructions (Superscript III cDNA synthesis system; Invitrogen). In all cases ~10% of the cDNA product was used in a 50 μ L PCR reaction that contained 2 μ M each forward and reverse primers. For quantitative PCR (qPCR) SYBR green system (Invitrogen) was used. Otherwise, cDNA was amplified (25 cycles) and the products resolved on 1.2 % agarose gel and visualized by ethidium bromide staining.

Gene	Forward primer	Reverse primer	Annealing temp. (°C)	Product size (bp)
DLL1	ACCTTCTTTCGCGTATGCCTCAAG	AGAGTCTGTATGGAGGGCTTC	58	222
DLL4	CGAGAGCAGGGAAGCCATGA	CCTGCCTTATACTCTGT	58	379
JAG1	ATTCGATCTACATAGCCTGTGAG	CTATACGATGTATTCCATCCGGT	50	671
JAG2	TGTCAGCCACGGAGCAGTCATT	TCTCACGTTCTTTCCTGCGCTT	50	469
CD200	TGGTCGTCTCTTCTCCACA	CTCCTGAATACCAGACTGCC	50	196

Antibodies and Fluorescence activated cells sorting (FACS): Anti-mouse antibodies for FACS were: PE-conjugated anti-mouse CD8a (clone 53-6.7; BD Pharmingen), AF700-conjugated anti-mouse CD44 (IM7; BD Pharmingen), e450-conjugated anti-mouse FoxP3 (FJK-16s, eBioscience), anti-CD3e (500A2; Biolegend), anti-CD8a (5H10; Caltag), anti-CD4 (RM4-5; BD Pharmingen), V450-conjugated CD45.1 (A20; BD Biosciences), PE-Cy7 conjugated anti-CD45.2 (104; BD Biosciences) and anti-CD25 (Clone PC61; BD Pharmingen). Functional grade anti-CD3 (17A2) and anti-CD28 (37.51) were purchased from eBioscience. For FACS cells were blocked with anti-mouse FcγRIII/IIIR (BD Pharmingen) for 10 m and then stained for 45 m on ice with fluorophore-conjugated antibody. Stained cells were washed, fixed with 3% paraformaldehyde and analyzed on LSRII instrument with CellQuest (BD Biosciences) software. Data analyses were performed with FlowJo software (version 8.73; Tree Star).

Serum CTX measurements: Food was withdrawn 6 to 10 h prior to bleeding. Peripheral blood (100 to 200 µl), obtained via sub-mandibular vein, was allowed to clot for one hour at room temperature and serum collected by spinning down the cell pellet (1000xg for 10 m). Serum was flash frozen and stored at -80°C. Serum C-terminal telopeptide of type 1 collagen (serum CTX) was measured using ELISA according to the manufacturer's instructions (Immunodiagnostic Systems, Plc.)

Matrix dissolution assays: CD8 T-cells were isolated from the bone marrow cells (isolated as described in OC generation section above) using magnetic beads. The T_{REG} were further purified in some experiments by cell sorting and co-cultured with OC (5×10^5) that were previously seeded on 24-well hydroxyapatite coated plates (Corning). M-CSF and GST-RANKL were added every 48 h. On day 5, cells were removed with 10% bleach and pit area was photographed and quantified using NIH ImageJ.

µCT data collection and analysis: The bones were scanned in µCT40 (Scanco Medical) at 55 kV, 145 µA, and resolution of 16 µm. Gauss sigma of 1.2, Gauss support of 2, lower threshold of

237, and upper threshold of 1000 were used for all the analysis. Regions of interest were selected 50 slices below the growth plate of the proximal tibia to evaluate the trabecular compartment. Bone mineral density was obtained by quantitative μ CT using Scanco Phantoms for calibration (43). All μ CT data and bone histomorphometry data was collected and analyzed by C.Y. who was blinded to the treatment performed on the mouse samples.

Statistical Analysis: Statistical significance was assessed in all cases using paired two-tailed Mann-Whitney U test in GraphPad Prism 5.0f. One-way and two-way ANOVA was performed in GraphPad Prism 5.0f.

RESULTS:

Low dose of RANKL activates osteoclasts to induce T_{CREG}: We first determined the dose-response of T_{CREG} production by RANKL in the bone marrow. RANKL was administered into FoxP3^{eGFP} reporter mice (44) at various doses for two consecutive days. Fifty hours after first dose, the mice were sacrificed and the numbers of CD8 T-cells that were GFP positive cells in the bone marrow were measured. This time was chosen because *in vitro* T_{CREG} require 48 to 50 h for maximal induction (7). The lowest dose of RANKL (0.125 mg/kg) induced the largest proportion of FoxP3⁺ CD8 T cells (Fig. 1A). No change in T_{CREG} levels was observed in the spleen (Fig. 1A), strongly suggesting that RANKL mediates on T_{CREG} its effect via osteoclasts. To assess that RANKL activated osteoclasts, we also measured serum CTX levels. These results (Fig. 1B) are consistent with our previous study where we demonstrated in mice that CD8 T-cells were bone protective and adoptive transfer of CD8 T-cells from *Scurfy* mice (i.e. FoxP3^{-/-}) did not protect against the osteolytic effects of RANKL (10). The increased levels of FoxP3 in response to RANKL in the bone marrow could either be due to recruitment of T_{CREG} to the bone marrow or induction of FoxP3 expression in cells that were FoxP3 negative.

To distinguish between recruitment and induction we FACS sorted a naïve GFP negative population of CD8 T-cells (Thy1.2⁺ and CD44 negative) from the spleens and bone marrow of FoxP3^{eGFP} reporter mice (44) to high purity (Fig. 1D first panel) and adoptively transferred them into congenically marked (Thy 1.1) OT-I Rag^{-/-} mice. The OT-I Rag^{-/-} mice were used as recipients because they are not lymphopenic and because they lack endogenous T_{CREG}, which avoids issues with homeostatic proliferation and competition with endogenous T_{CREG}, respectively, and hence increases the sensitivity of the assay. In the absence of RANKL administration very low levels GFP⁺ CD8 T-cell were detected, but RANKL administration (0.125 mg/kg) yielded ~1% GFP⁺ Thy1.2 T-cells (Fig. 1C and 1D third panel). The conversion from GFP⁻ to GFP⁺ by low dose RANKL is a clear indication of T_{CREG} induction. To determine whether osteoclasts were responsible for T_{CREG} induction, we pretreated the OT-I Thy1.1 Rag^{-/-} mice with the bisphosphonate, Zoledronic acid (ZA), two weeks prior to transferring GFP⁻ cells. As the half life of ZA in plasma is ~20 minutes (45) but ~ 60 days in the bone (46), we expect no direct effect of ZA 14 days post-treatment on the transferred T-cells. In mice treated with ZA (Fig. 1C), no conversion of CD8 T-cells to GFP⁺ was observed indicating that actively resorbing

osteoclasts are required for T_{CREG} induction. These results show that RANKL leads to induction of endogenous T_{CREG} in the reporter mice and in adoptive transfer T-cell model.

We had concerns that the GST-RANKL fusion protein used in these experiments, which can form dimers or higher order oligomers through the GST moiety (47), could be activating osteoclasts to induce T_{CREG} non-physiologically. To allay this concern, commercially purchased recombinant mouse RANKL (i.e. non-fused) was used for assessing changes in T_{CREG} levels in the bone marrow and spleen. Murine-RANKL lacking the GST moiety gave identical results as shown in Fig. 1A (data not shown). Taken together with our *in vitro* results that osteoclasts induce T_{CREG}, this experiment establishes that activation of resorption by osteoclasts by low-dose RANKL induces T_{CREG}.

Equivalent levels of T_{CREG} in ovariectomized and sham-operated mice: Based on the finding that activation of osteoclast induces T_{CREG} we reasoned that T_{CREG} should be induced by ovariectomy, as estrogen-depletion activates osteoclasts leading to osteoporosis. Therefore, we compared levels of T_{CREG} in the bone marrow of sham-operated and ovariectomized mice. As shown in Fig. 2A, T_{CREG} were present in ovariectomized mice, but no increase in levels of T_{CREG} was observed between the sham-operated and ovariectomized mice (24 days post-ovariectomy). At this time point, we also observed no significant difference either in the number or percent (relative to CD3⁺ cells) of CD8 T-cells in the bone marrow between sham-operated and ovariectomized mice.

We next assessed the endogenous T_{CREG} for their ability to suppress osteoclasts from both sham-operated and ovariectomized mice. To this end we isolated the GFP⁺ CD8 T-cells from the bone marrow space of ovariectomized and sham operated mice by cell sorting. Equivalent numbers of T-cells (5×10^4 cells/well) and osteoclasts (1×10^5) were tested in a bone matrix dissolution assay. The results show that T_{CREG} from both the ovariectomized and sham operated mice were effective in suppressing osteoclast bone resorbing activity *in vitro* (Fig. 2B).

Osteoclast abundance increases in estrogen-depleted animal through a Fas ligand-dependent mechanism (48,49). The simplest interpretation of these results is that while the T_{CREG} present in ovariectomized mice are functional, but their abundance relative to the number of osteoclasts is insufficient to limit bone resorption leading to osteoporosis. Further, increasing the number of T_{CREG} in ovariectomized mice either by adoptive transfer or by induction should ameliorate

osteoporosis. What remains unclear is why are T_{CREG} not induced in estrogen-depleted animals despite increased osteoclast activity?

IL-17 and TNF α suppresses T_{CREG} induction by osteoclasts: It has been reported that menopause leads to a low level persistent production of effector T-cells [T_{EFF}; (50)]. We hypothesized that in the presence of pro-inflammatory cytokines, osteoclasts fail to induce T_{CREG}. To test this hypothesis, we measured OC-iT_{CREG} induction in the presence of IL-17 and TNF α . Antigen-pulsed osteoclasts were co-cultured with OT-I CD8 T-cells in the presence of RANKL and TNF α or IL-17. Indeed, in the presence of 10 ng/ml IL-17 (Fig. 3A) or increasing TNF α concentrations (Fig. 3B), the induction of T_{CREG} by osteoclasts was greatly impaired. Equal levels of suppression in T_{CREG} induction was observed at doses of 2 to 50 ng/ml IL-17A, therefore only the effect of only one dose is shown. Effect of similar dose of IL-17A has been observed in alveolar cells (51). We tested two different concentrations of RANKL to ascertain if the ratio of RANKL to TNF α acts as determinant of T_{CREG} induction. Our data (Fig. 3B) did not support the notion that the ratio of TNF α to RANKL is important for T_{CREG} induction. To understand the underlying mechanism of how TNF α affects osteoclasts' ability to induce T_{CREG}, we investigated the signals provided by osteoclasts to induce FoxP3 in the CD8 T-cells. Concurrently we assessed if these signals were affected by TNF α or IL-17.

Osteoclasts use CD200 as costimulatory signal to induce T_{CREG}: Antigen presenting cells typically activate CD8 T-cells through three signals: antigen presented in the context of MHC class-I, a co-stimulatory signal, and finally a polarization signal that determines the effector phenotype of the T-cell. We have previously shown that osteoclasts cross-present antigens, and antigen presentation is required for T_{CREG} induction (7,8). Here we wanted to identify the co-stimulatory signal provided by osteoclasts and to test if pro-inflammatory cytokines would regulate the expression of this molecule(s).

The most common and well-studied costimulatory signals on antigen-presenting cells are CD80 and CD86. As CD80/CD86 double knockout mice are commercially available, we generated osteoclasts from these mice. The CD80/CD86 null osteoclasts (as well as wild-type controls) were then used to prime OT-I T-cells in the presence and absence of antigen. We found that the osteoclasts derived from CD80/CD86^{-/-} mice were able to induce T_{CREG} as effectively as wild-type controls (Fig. 4A). OT-I CD8 T-cells activated by CD80/CD86 null

osteoclasts produced IL-6, IL-2 and IFN- γ to levels indistinguishable from wild-type mice (Fig. 4B). Having ruled out CD80/CD86 as the costimulatory molecules, we queried our osteoclast microarray dataset (6) for other costimulatory molecules expressed by osteoclasts. We found that osteoclasts express CD200 (up regulated 8.2 ± 1.2 fold relative to pre-osteoclasts; $P \leq 10^{-4}$) and c-Mer (upregulated 4.4 ± 0.9 fold; $P \leq 0.008$). We chose to test the role of CD200 based on the phenotype of CD200^{-/-} mice and the reported role for CD200 in regulating T_{REG} (52-54). Treatment of OT-I CD8 T-cells with (soluble) CD200-Fc prior to co-culturing with osteoclasts impaired FoxP3 induction (Fig. 4C). In contrast, treatment of the OT-I CD8 T-cells with a control IgG1-Fc had no effect on FoxP3 induction (Fig. 4C). Consistent with a previous study (55), quantitative real-time PCR (qPCR) shows that CD200 is not expressed in osteoclast precursors but is expressed in mature osteoclasts (i.e. was induced by RANKL in the precursors; Fig. 4D). CD200 mRNA expression was not affected by treatment of osteoclasts with TNF α or IL-17 (Fig. 4D). These results show that osteoclasts use CD200, which is expressed in mature osteoclasts, as a costimulation signal for FoxP3 induction.

Osteoclasts induce T_{REG} using the Notch ligand DLL4: The most well characterized inducer (i.e. polarizing signal) of FoxP3 in T-cells is TGF β . We have previously shown that neutralization or addition of TGF β has no effect on the induction of T_{REG} (8). We therefore sought to identify other pathways that can regulate the FoxP3 promoter in T-cells. A number of previous studies have identified that Notch signaling contributes to FoxP3 induction (56-59). To test if Notch signaling is important for T_{REG} induction by osteoclasts, we initially used the γ -Secretase inhibitor DAPT. Ligation of the Notch receptor by its ligand leads to cleavage of Notch by γ -secretase to release Notch intra-cellular domain (60). Inclusion of 10 μ M DAPT in co-cultures of osteoclasts and OT-I CD8 T-cells completely abrogated FoxP3 induction (Fig. 5A). Next, we identified the Notch ligands expressed in osteoclasts using reverse-transcription followed by PCR. We found that of the five Notch ligands encoded in the mouse genome, mature osteoclasts express: Jagged (Jag)1, Jag2, Delta-like (DLL)1 and DLL4 (Fig. 5B). Of the four, the osteoclast-precursors (bone marrow cells treated with M-CSF but not RANKL) express all of the ligands except DLL4 (data not shown and Fig. 5C). Surprisingly, DLL4 transcription was significantly repressed in mature osteoclasts after culturing overnight in 20 ng/ml TNF α or 10 ng/ml IL-17 (Fig. 5C). To assess the role of DLL4 in T_{REG} induction we added (soluble) DLL4-Fc to OT-I CD8 T-cells prior to co-culturing with osteoclasts. DLL4-Fc effectively

abrogated T_CREG induction by osteoclasts (data not shown). To assess the role of DLL4 *in vivo* we performed the *in vivo* induction experiment as described in Fig. 1: (polyclonal) GFP⁺ CD8 T-cells from FoxP3^{eGFP} reporter mice (44) were purified by cell sorting and transferred into OT-II Rag^{-/-} mice. Two hours prior to RANKL treatment, DLL4-Fc (30 mg/kg given intravenously) or a control IgG1-Fc, were injected intravenously into the recipient mice. Low-dose RANKL (0.125 mg/kg) was then administered on two consecutive days. No induction of T_CREG was observed in mice receiving DLL4-Fc (Fig 5D). These results demonstrate that osteoclasts use Notch ligand DLL4 to signal into CD8 T-cells to induce the expression of FoxP3.

DLL-4 expression is repressed in the presence of TNF α and IL-17 but can be de-repressed by RANKL: Having identified that DLL4 was required for osteoclasts to induce Foxp3 expression in CD8⁺ T cells we next tested if DLL-4 expression was affected by the pro-inflammatory cytokines. As RANKL induced DLL4 in osteoclast precursors, we hypothesized that adding additional RANKL may overcome the repression of DLL4 by TNF α . To assess the reversibility of DLL4 expression, mature osteoclasts were cultured overnight in 50 ng/ml RANKL and 20 ng/ml TNF α , and then additional RANKL was added to the culture media (while maintaining 20 ng/ml TNF α). Indeed, addition of RANKL overcomes (Fig. 5E; within 24 hours) the repression of DLL4 by TNF α as assessed by qPCR. Based on this result, we tested the ability of RANKL to restore induction of T_CREG by osteoclasts. The experiment was performed as above, but in this case FoxP3 induction in OT-I CD8 T-cells in the presence of OVA was measured at either 10 ng/ml or 20 ng/ml TNF α (Fig. 5F). Consistent with restored expression of DLL4 on osteoclasts by RANKL the induction of T_CREG was also restored in the presence of TNF α . Our results indicate that TNF α repressed DLL4 expression and that addition of RANKL could de-repress the effect of TNF α leading to increased DLL4 expression and to increased T_CREG induction by osteoclasts.

Low dose RANKL induces functional T_CREG in ovariectomized mice: Next we tested the ability of RANKL to induce T_CREG in ovariectomized mice as proof of principle for de-repression by increased levels of RANKL, in pro-inflammatory environment. Here again, the dose of RANKL that induced the highest levels of T_CREG *in vivo* was used (Fig. 1A). Low dose RANKL (ldRL = 0.125 mg/kg) was administered two weeks after ovariectomy. After 10 days of RANKL administration T_CREG levels increased by an average of 3.6-fold relative to untreated mice (Fig.

6A). We administered low-dose RANKL two weeks post-ovariectomy because peak bone loss occurs in the tibia in rodents at this time (61,62). Additionally, effector T-cell levels also peak two-weeks post-ovariectomy (63,64). To determine if the induced $T_{C_{REG}}$ are functional, bone resorption and bone formation rates in these (low-dose) RANKL-treated mice was assessed. As we have previously established that *ex vivo* generated OC- $iT_{C_{REG}}$ limit bone resorption, increase bone mass, decrease activated effector T-cells, and increase bone formation and mineral apposition rates (10), we used this treatment as a benchmark in these experiments. Obtaining the same effect by low-dose RANKL and $T_{C_{REG}}$ also indicates that the effect on bone parameters is, in fact, due to the effect of $T_{C_{REG}}$.

Ovariectomized mice treated with low-dose RANKL had lower levels of serum CTX compared to mice treated with OC- $iT_{C_{REG}}$ (Fig. 6B left panel). We also observed fewer osteoclasts per unit area of bone surface (Fig. 6B center panel) and less bone surface was occupied by osteoclasts (Fig. 6B right panel). The low-dose RANKL treated mice also had increased bone volume (BV/TV), increased bone mineral density (Fig. 6C) and improved trabecular bone parameters (Fig. S1) relative to the adoptively transferred OC- $iT_{C_{REG}}$ and ZA treated mice. Finally, the low-dose RANKL treated mice also had increased bone formation and mineral apposition rates over the adoptively transferred OC- $iT_{C_{REG}}$ treated mice (Fig. 6D). Ovariectomy increases proinflammatory effector T-cells (T_{EFF} ; $CD3^+ CD44^+$) in the bone marrow (Fig. 6E). In contrast to ZA treatment, low-dose RANKL decreased the levels of T_{EFF} in the bone marrow (Fig 6E). The suppression of T_{EFF} production is consistent with the regulatory T-cell activity of osteoclast-induced $T_{C_{REG}}$ (7). Together, these results indicate that $T_{C_{REG}}$ induced by low-dose RANKL was a more effective treatment than adoptive transfer of OC- $iT_{C_{REG}}$ and than the bisphosphonate ZA.

The effect of low-dose RANKL is mediated through $T_{C_{REG}}$: As adoptive transfer of $T_{C_{REG}}$ and low-dose RANKL give the same phenotype *viz.* decrease in bone resorption, increase bone formation, and decrease in T_{EFF} in the bone marrow, these results support our hypothesis that ovariectomy leads to a deficit in $T_{C_{REG}}$ numbers. Nonetheless, to directly confirm that low-dose RANKL mediates its effect in ovariectomized mice through $T_{C_{REG}}$ we used mice that lack CD8 T-cells ($\beta 2M^{-/-}$). In the absence of CD8 T-cells, $T_{C_{REG}}$ cannot be generated and therefore we anticipated that low-dose RANKL would have no effect on bone resorption, ($CD44^+$) effector T-cells, or bone formation as observed in wild-type mice. Our results show that relative to sham-

operated mice ovariectomized $\beta 2M^{-/-}$ mice treated with low-dose RANKL administration had increased levels of effector T-cells (Fig. 7A) and bone resorption (Fig. 7B). The increased bone loss in ovariectomized mice and mice treated with low-dose RANKL were corroborated by μ CT (Fig. 7C and D). Furthermore, as $\beta 2M^{-/-}$ mice have an intact CD4 T-cell compartment, our results show that (FoxP3⁺ CD4) T_{REG} are not able to substitute for the loss of T_{CREG}, indicating a unique role for T_{CREG}.

Finally, as all doses of RANKL induce T_{CREG} (Fig. 1A), we tested if high dose of RANKL (e.g. 1 mg/kg) provides a bone anabolic effect in ovariectomized mice. Our data shows that high doses of RANKL promote bone resorption in both estrogen replete and deficient mice and in CD8 deficient mice relative to low-dose RANKL (Fig. 7E). In this comparison, it is noteworthy that $\beta 2M^{-/-}$ mice lost significant levels of bone by ovariectomy alone (75% in $\beta 2M^{-/-}$ mice versus 28% in WT mice), indicating that endogenous T_{CREG} (*i.e.* not induced by low-dose RANKL treatment) are partially successful in limiting bone loss. This result is consistent with our hypothesis that the abundance of endogenous T_{CREG} is insufficient relative to the abundance of osteoclasts in estrogen-depleted animals. Low-dose RANKL was only effective in limiting bone loss through T_{CREG} because this effect is only observed in CD8 T-cell-sufficient mice. High-dose RANKL activates osteoclasts and induces T_{CREG} in wild-type mice, but the T_{CREG} induction is apparently insufficient to limit bone loss and counter the effect of RANKL on the osteoclasts. These results show that RANKL has a biphasic effect: it activates osteoclasts to induce T_{CREG} at low doses, but at high doses RANKL overrides the limiting effect of the T_{CREG}. Our results indicate that T_{CREG} act as homeostatic buffering system to “smooth out” variations in RANKL levels to limit bone loss. Increasing the levels of T_{CREG} by RANKL pulse can compensate and restore balance from bone loss to bone formation.

DISCUSSION:

All organisms need to maintain physiological stability to survive changes in their environment. A number of mechanisms have evolved to achieve this physiological stability, chiefly positive and negative feedback loops. Our studies have revealed such a negative feedback loop between osteoclasts and CD8 T-cells that appears to be important for bone and immune homeostasis (9). Our study demonstrates that T_CREG induction, while not critical for globally regulating the aberrant activation of self-reactive T-cells, are important in local immune suppression.

Here we used a low-dose of RANKL, which induces the highest proportion of T_CREG in bone marrow (Fig. 1) to induce T_CREG in ovariectomized mice. We show that the low-dose RANKL-induced T_CREG are functional: they limit bone loss in the estrogen-depleted mice. As *ex vivo* generated T_CREG (produced under a non-inflammatory environment) also limit bone loss, are immunosuppressive and increase bone formation, our results indicate that the overall loss of T_CREG induction contributes to the observed osteoporosis. Furthermore, as T_CREG adoptive transfer recapitulates the same effect as the induced T_CREG on bone and the immune system indicates that other cell types contribute minimally, if at all.

To understand the reason for the lack of T_CREG induction, we examined the effect of TNF α and IL-17 on T_CREG induction by osteoclasts *in vitro*. IL-17, expressed by T_H17 has been previously shown to increase bone loss (65). Inhibition of IL-17 signaling has also been shown to ameliorate bone loss in ovariectomized mice (66,67). Similarly, TNF α increases in ovariectomized mice (63,64,68) and disruption of TNF α signaling protects against bone loss post-ovariectomy(69). Consistent with lack of increase of T_CREG in ovariectomized mice, T_CREG induction by osteoclasts was inhibited in the presence of TNF α or IL-17 in culture. These results indicate that the proinflammatory cytokines increase bone resorption, but repress T_CREG induction by osteoclasts. To understand the mechanism for the loss of T_CREG induction, we examined the signals that osteoclasts provide to CD8 T-cells. We have previously demonstrated that antigen presentation is required for T_CREG induction (7,8). Here we identified CD200 as a costimulatory molecule used by osteoclasts to induce T_CREG (Fig. 4). While CD200 is induced by RANKL, the expression levels of CD200 were not affected by TNF α or IL-17. CD200 has been shown to decrease bone mass via its effect on osteoclasts (55). Moreover, and consistent with our results with T_CREG induction, CD200 knockout mice are also more susceptible to bone loss in the collagen-induced arthritis model (70).

Notch signaling has been previously been identified in impacting FoxP3 expression in T-cells (57,58,71). Therefore, we tested for the role of Notch signaling in T_{CREG} induction. We identified that DLL4, expressed on mature osteoclasts but not in osteoclast precursors, was required for FoxP3 expression in CD8 T-cells. As Notch signaling plays an important role in osteoclast (72,73) and osteoblast differentiation (74) these results will be important for correctly interpreting the role of Notch ligand-receptor interactions in bone remodeling (75). Blockade of DLL4 abrogated T_{CREG} induction *in vivo*, and DLL4 expression was repressed in the presence of IL-17 and TNF α , which concomitantly suppressed T_{CREG} induction by osteoclasts. Further, adding back RANKL reversed DLL-4 repression and restored T_{CREG} induction by osteoclasts (Fig 7F). Thus, T_H17 could limit the ability of osteoclasts to induce T_{CREG} by reducing the expression of DLL4, an effect moderated by the addition of RANKL. A genetic test for the requirement of DLL4 in inducing T_{CREG} will require generation of osteoclast-specific DLL4 deletion.

It is remarkable that administering low-dose RANKL leads to reduced bone loss and increased bone formation because RANKL is exclusively believed to be a pro-resorptive. This result could not be predicted or understood in the absence of the knowledge of the osteoclast-T_{CREG} feedback loop elucidated here. Low-dose RANKL is anabolic because it maximally induces T_{CREG} and engages the feedback loop, but also because T_{CREG} reduce the proinflammatory T_{EFF}. Thus, low-dose RANKL induction of T_{CREG} not only decreases the number of osteoclasts but also reduces, or eliminates, the production of the cytokines that drive osteoclast activity (Fig. 7F).

RANKL is produced by osteoblasts and osteocytes in both a membrane-bound and soluble form (76,77). To regulate osteoclast activity and numbers these cells also secrete osteoprotegrin (OPG), which binds to RANKL and competes to prevent RANK (receptor) activation. Assessing the levels of biologically active RANKL *in vivo* therefore is challenging because it is neither accurate nor precise. The situation in osteoporosis is further complicated by presence of pro-resorptive cytokines that directly affect both the osteoclasts activities: bone resorption and activation of CD8 T-cells. Nonetheless, it has been shown that reducing RANKL levels is beneficial by anti-RANKL therapies: Prolia (Denosumab) (78), and by OPG (79) for postmenopausal osteoporosis. However, this raises the question: if there are significant level of endogenous RANKL already produced postmenopause, how is a small change in RANKL level sensed by osteoclasts to induce DLL4 expression? One possible explanation is that the system is

Accepted Article

finely balanced in osteoporosis, such that low-dose RANKL can mediate its affect on osteoclasts. Alternatively, delivering RANKL as a pulse is important. For example, parathyroid hormone (PTH) demonstrates differences in how it is delivered: whereas, intermittent doses of PTH are anabolic, continuous exposure lead to bone loss (80). Additional studies are needed to understand this phenomenon.

While RANKL, TNF α and IL-17 all promote bone resorption, RANKL induces T_{CREG} induction to limit bone loss (Fig. 7F). In contrast, TNF α and IL-17 suppress (at the transcriptional level) the expression of DLL4 in osteoclasts, one of the signals required for T_{CREG} induction. Therefore, DLL4 unexpectedly acts as a switch for T_{CREG} induction in osteoclasts in response to TNF α or RANKL. Consistent with the *in vitro* observations we observed an increase in T_{CREG} levels in ovariectomized mice treated with low dose RANKL. Nonetheless, at doses above 0.5 mg/kg (Fig. 1A and 7E) or prolonged (> 5 days) dosing RANKL promotes bone resorption in estrogen-replete (81) and ovariectomized mice (Fig. 7E). Indeed, whereas low dose RANKL may be in the physiological range, high doses (i.e. 1 mg/kg) used to promote bone resorption are super-physiological (in the sense that this dose exceeds RANKL levels experienced by an animal during life). This work is the first demonstration of RANKL having a biphasic response. There are a number of demonstrated examples in biology (82) of mediators that produce a biphasic response.

Regulatory T-cells (T_{REG}) are a subset of CD4⁺ T cells that play a critical role in negatively regulating self-reactive T-cells and in resolving inflammatory responses. It is well documented that a reduction in the number and/or function of T_{REG} causes the breakdown of immunological tolerance leading to lymphoproliferation and autoimmune diseases (11,17,26). However, it is not clear why T_{REG} fail to control inflammation in some individuals that develop autoimmune diseases. One reason suggested for this loss of tolerance is due to T_{REG} instability (or more explicitly conversion of ex-T_{REG} to T_{H17} cells (83)) when exposed to an inflammatory environment (84). Our inquiry of why T_{CREG} fail to suppress osteoclast activity and allow osteoporosis to develop followed a similar line of investigation. Our results indicate that inflammatory cytokines do not lead to defects in T_{CREG}, but suppress induction of T_{CREG} by osteoclasts (i.e. the antigen-presenting cells) through regulating DLL4 expression. By extension, our results are consistent with the emerging paradigm that inflammatory cytokines (i.e. induced by adjuvant or PAMPS) affect the antigen-presenting cells, and not the T_{REG}, to tip the balance

from induction of tolerance towards immunity (85,86). Further studies are needed to determine the mechanisms underlying the effect on antigen-presenting cells for T_{REG} activation.

Our laboratory was first to establish that murine osteoclasts have an antigen presentation activity and prime CD8 T-cells (7). Li et al. have shown that human peripheral blood-derived osteoclasts can also prime T-cells (87). This study is the first *in vivo* demonstration that osteoclasts can induce FoxP3⁺ CD8 T-cells and to verify these T_{REG}, although induced under inflammatory conditions are functional in that they are immunosuppressive and anti-resorptive. These studies also, therefore establish a proof-of-concept that induction of T_{REG} can be used for the treatment of osteoporosis in a well-accepted murine model of human postmenopausal osteoporosis (88).

Summarizing, we have shown that low doses of RANKL activate osteoclasts to induce T_{REG}. We show that in the presence of TNF α and IL-17, T_{REG} induction is suppressed. We have identified CD200 and DLL4 as costimulatory and differentiation signals respectively, used by osteoclasts to induce T_{REG}. Furthermore, we demonstrate that TNF α and IL-17 suppress DLL4 expression, and thus providing a plausible mechanism for why despite increased activity of the osteoclasts in ovariectomized mice, T_{REG} levels are not increased. Thus, *in vitro* DLL4 acts as a switch that responds to TNF α and IL-17 to turn off T_{REG} induction. RANKL turns on DLL4 expression and concomitantly T_{REG} induction. Finally, we demonstrate that low dose RANKL induces functional T_{REG} in ovariectomized mice leading to lower bone resorption, increased bone mass and density and increased formation of new bone. Thus, low dose RANKL has the potential to be a novel therapy to treat postmenopausal osteoporosis and perhaps other inflammatory bone erosion diseases. Induction of T_{REG} offers an advantage over anti-RANKL and bisphosphonate therapy because it not only inhibits bone resorption and promotes new bone formation, but because as we show T_{REG} also decrease the levels of pro-inflammatory effector T-cells in ovariectomized mice [this study and (10)] and have the potential to restore immune homeostasis as well.

ACKNOWLEDGEMENTS:

We are grateful for assistance provided by Department of Comparative Medicine, in particular by Erin Touchette and Dr. Cheri West. We thank Dr. Steve Teitelbaum for providing the GST-RANKL bacterial expression system, as well as for discussion and advice. Crystal Idleburg is acknowledged for preparing slides for histomorphometry. Washington University Musculoskeletal Research Core (NIH P30 AR057235) provided partial support for these studies. Research reported in this study was partially supported by National Institute of Arthritis and Musculoskeletal and Skin Disease of the NIH under Award Number RO1AR064821 to R.A.

Author Contributions: R.A. and Z.B. designed the experiments with advice from D.V.N. and R.D.P. Experiments were carried out by Z.B., S.N., J.K., E.V.S., A.C., and R.A. Readouts of bone histomorphometry and μ CT was collected and analyzed by C.Y. or J.L.D. who were blinded to treatments. Z.B., D.V.N., R.D.P. and R.A. interpreted the experiments. R.A. wrote the manuscript with input from Z.B, D.V.N and R.D.P.

References cited:

1. Arron JR, Choi Y 2000 Bone versus immune system. *Nature* **408**(6812):535-536.
2. Rauner M, Sipos W, Thiele S, Pietschmann P 2013 Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. *Int Arch Allergy Immunol* **160**(2):114-125.
3. Schett G 2009 Osteoimmunology in rheumatic diseases. *Arthritis Res Ther* **11**(1):210.
4. Takayanagi H 2005 Inflammatory bone destruction and osteoimmunology. *J Periodontal Res* **40**(4):287-293.
5. Takayanagi H 2012 New developments in osteoimmunology. *Nat Rev Rheumatol* **8**(11):684-689.
6. Kiesel J, Miller C, Abu-Amer Y, Aurora R 2007 Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. *Dev Dyn* **236**(8):2181-2197.
7. Kiesel JR, Buchwald ZS, Aurora R 2009 Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. *J Immunol* **182**(9):5477-5487.
8. Buchwald ZS, Kiesel JR, DiPaolo R, Pagadala MS, Aurora R 2012 Osteoclast Activated FoxP3(+) CD8(+) T-Cells Suppress Bone Resorption in vitro. *PLoS ONE* **7**(6):e38199.
9. Buchwald ZS, Aurora R 2013 Osteoclasts and CD8 T Cells Form a Negative Feedback Loop That Contributes to Homeostasis of Both the Skeletal and Immune Systems. *Clin Dev Immunol* **2013**:Article ID 429373.
10. Buchwald ZS, Kiesel J, Yang C, DiPaolo R, Novack D, Aurora R 2013 Osteoclast-induced Foxp3+ CD8 T-Cells Limit Bone Loss in Mice. *Bone* **56**:163-173.
11. Khattri R, Cox T, Yasayko SA, Ramsdell F 2003 An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat Immunol* **4**(4):337-342.

12. Allez M, Brimnes J, Dotan I, Mayer L 2002 Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. *Gastroenterology* **123**(5):1516-1526.
13. Banham AH, Powrie FM, Suri-Payer E 2006 FOXP3+ regulatory T cells: Current controversies and future perspectives. *Eur J Immunol* **36**(11):2832-2836.
14. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L 2005 Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. *J Immunol* **174**(9):5814-5822.
15. Colovai AI, Mirza M, Vlad G, Wang S, Ho E, Cortesini R, Suci-Foca N 2003 Regulatory CD8+CD28- T cells in heart transplant recipients. *Hum Immunol* **64**(1):31-37.
16. Correale J, Villa A 2010 Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. *Ann Neurol* **67**(5):625-638.
17. Fontenot JD, Gavin MA, Rudensky AY 2003 Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* **4**(4):330-336.
18. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY 2007 Foxp3-dependent programme of regulatory T-cell differentiation. *Nature* **445**(7129):771-775.
19. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF 2007 CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. *Clin Cancer Res* **13**(23):6947-6958.
20. Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E, Fietta AM 2006 Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. *Hum Immunol* **67**(1-2):1-12.
21. Niederkorn JY 2008 Emerging concepts in CD8(+) T regulatory cells. *Curr Opin Immunol* **20**(3):327-331.

22. Shevach EM 2006 From vanilla to 28 flavors: multiple varieties of T regulatory cells. *Immunity* **25**(2):195-201.
23. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM 2006 The lifestyle of naturally occurring CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells. *Immunol Rev* **212**:60-73.
24. Stephens GL, Andersson J, Shevach EM 2007 Distinct subsets of FoxP3⁺ regulatory T cells participate in the control of immune responses. *J Immunol* **178**(11):6901-6911.
25. Rudensky A 2005 Foxp3 and dominant tolerance. *Philos Trans R Soc Lond B Biol Sci* **360**(1461):1645-1646.
26. Kim JM, Rasmussen JP, Rudensky AY 2007 Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat Immunol* **8**(2):191-197.
27. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T 2001 Immunologic tolerance maintained by CD25⁺ CD4⁺ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. *Immunol Rev* **182**:18-32.
28. Blair PJ, Bultman SJ, Haas JC, Rouse BT, Wilkinson JE, Godfrey VL 1994 CD4⁺CD8⁻ T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. *J Immunol* **153**(8):3764-3774.
29. Mayer CT, Floess S, Baru AM, Lahl K, Huehn J, Sparwasser T 2011 CD8⁺ Foxp3⁺ T cells share developmental and phenotypic features with classical CD4⁺ Foxp3⁺ regulatory T cells but lack potent suppressive activity. *Eur J Immunol* **41**(3):716-725.
30. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM 2003 Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med* **198**(12):1875-1886.
31. Blander JM 2007 Signalling and phagocytosis in the orchestration of host defence. *Cell Microbiol* **9**(2):290-299.

32. Villadangos JA, Schnorrer P, Wilson NS 2005 Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. *Immunol Rev* **207**:191-205.
33. Suzuki M, Jagger AL, Konya C, Shimojima Y, Pryshchep S, Goronzy JJ, Weyand CM 2012 CD8+CD45RA+CCR7+FOXP3+ T Cells with Immunosuppressive Properties: A Novel Subset of Inducible Human Regulatory T Cells. *J Immunol* **189**(5):2118-2130.
34. Lerret NM, Houlihan JL, Kheradmand T, Pothoven KL, Zhang ZJ, Luo X 2012 Donor-Specific CD8(+) Foxp3(+) T Cells Protect Skin Allografts and Facilitate Induction of Conventional CD4(+) Foxp3(+) Regulatory T Cells. *Am J Transplant* **12**(9):2335-2347.
35. Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, Varelias A, Alexander KA, Teal BE, Sparwasser T, Hammerling GJ, Markey KA, Koyama M, Clouston AD, Engwerda CR, Hill GR, MacDonald KP 2012 Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. *Blood* **119**(24):5898-5908.
36. Anderson ME, Jr., Buchwald ZS, Ko J, Aurora R, Sanford T 2014 Patients with Pediatric Obstructive Sleep Apnea Show Altered T-Cell Populations with a Dominant TH17 Profile. *Otolaryngol Head Neck Surg*.
37. Siegmund K, Ruckert B, Ouaked N, Burgler S, Speiser A, Akdis CA, Schmidt-Weber CB 2009 Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+ T cells. *J Immunol* **182**(4):2124-2130.
38. Savageau MA, Coelho PM, Fasani RA, Tolla DA, Salvador A 2009 Phenotypes and tolerances in the design space of biochemical systems. *Proc Natl Acad Sci U S A* **106**(16):6435-6440.
39. Savageau MA 2001 Design principles for elementary gene circuits: Elements, methods, and examples. *Chaos* **11**(1):142-159.
40. Savageau MA 1974 Optimal design of feedback control by inhibition. *Journal of molecular evolution* **4**(2):139-156.

41. Sneppen K, Krishna S, Semsey S 2010 Simplified models of biological networks. Annual review of biophysics **39**:43-59.
42. Germain RN 2012 Maintaining system homeostasis: the third law of Newtonian immunology. Nat Immunol **13**(10):902-906.
43. Nazarian A, Snyder BD, Zurakowski D, Muller R 2008 Quantitative micro-computed tomography: a non-invasive method to assess equivalent bone mineral density. Bone **43**(2):302-311.
44. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, Chatila TA 2007 Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol **178**(5):2961-2972.
45. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A 2002 Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol **42**(11):1228-1236.
46. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H 2008 Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos **36**(10):2043-2049.
47. Maru Y, Afar DE, Witte ON, Shibuya M 1996 The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain. J Biol Chem **271**(26):15353-15357.
48. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S 2007 Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell **130**(5):811-823.
49. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M 2008 Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J **27**(3):535-545.

50. Pacifici R 2010 T cells: Critical bone regulators in health and disease. *Bone*.
51. Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KC, Guttentag S, Worthen GS 2011 IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. *J Immunol* **186**(5):3197-3205.
52. Gorczynski RM, Chen Z, Hu J, Kai Y, Lei J 2001 Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. *Clin Exp Immunol* **126**(2):220-229.
53. Mukhopadhyay S, Pluddemann A, Hoe JC, Williams KJ, Varin A, Makepeace K, Aknin ML, Bowdish DM, Smale ST, Barclay AN, Gordon S 2010 Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. *Cell Host Microbe* **8**(3):236-247.
54. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T 2008 A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. *Nat Immunol* **9**(9):1074-1083.
55. Cui W, Cuartas E, Ke J, Zhang Q, Einarsson HB, Sedgwick JD, Li J, Vignery A 2007 CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts. *Proc Natl Acad Sci U S A* **104**(36):14436-14441.
56. Bassil R, Zhu B, Lahoud Y, Riella LV, Yagita H, Elyaman W, Khoury SJ 2011 Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. *J Immunol* **187**(5):2322-2328.
57. Ou-Yang HF, Zhang HW, Wu CG, Zhang P, Zhang J, Li JC, Hou LH, He F, Ti XY, Song LQ, Zhang SZ, Feng L, Qi HW, Han H 2009 Notch signaling regulates the FOXP3 promoter through RBP-J- and Hes1-dependent mechanisms. *Mol Cell Biochem* **320**(1-2):109-114.

58. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, Das P, Golde TE, Osborne BA 2008 Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. *Blood* **112**(5):1813-1821.
59. Shen Z, Chen L, Hao F, Wu J 2009 Transcriptional regulation of Foxp3 gene: multiple signal pathways on the road. *Med Res Rev* **29**(5):742-766.
60. Borggreffe T, Oswald F 2009 The Notch signaling pathway: transcriptional regulation at Notch target genes. *Cell Mol Life Sci* **66**(10):1631-1646.
61. Jee WS, Yao W 2001 Overview: animal models of osteopenia and osteoporosis. *J Musculoskelet Neuronal Interact* **1**(3):193-207.
62. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC 1992 Increased osteoclast development after estrogen loss: mediation by interleukin-6. *Science* **257**(5066):88-91.
63. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O, Pacifici R 2003 Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. *Proc Natl Acad Sci U S A* **100**(18):10405-10410.
64. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R 2001 Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. *Proc Natl Acad Sci U S A* **98**(24):13960-13965.
65. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H 2006 Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. *J Exp Med* **203**(12):2673-2682.
66. Deselm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, Liu C, Choi Y, Kim YF, Zou W, Teitelbaum SL 2012 IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. *J Cell Biochem* **113**(9):2895-2902.

67. Deselm CJ, Zou W, Teitelbaum SL 2012 Halofuginone prevents estrogen-deficient osteoporosis in mice. *J Cell Biochem.*
68. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R 2000 Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. *J Clin Invest* **106**(10):1229-1237.
69. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I 1997 Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. *J Clin Invest* **99**(7):1699-1703.
70. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD 2000 Down-regulation of the macrophage lineage through interaction with OX2 (CD200). *Science* **290**(5497):1768-1771.
71. Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M, Ciuffetta A, Colantoni S, Vacca A, Frati L, Gulino A, Felli MP, Screpanti I 2011 Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. *J Immunol* **186**(11):6199-6206.
72. Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H 2012 Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. *Arthritis Res Ther* **14**(2):R45.
73. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL 2008 NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. *J Biol Chem* **283**(10):6509-6518.
74. Regan J, Long F 2013 Notch signaling and bone remodeling. *Curr Osteoporos Rep* **11**(2):126-129.
75. Zanotti S, Canalis E 2013 Notch signaling in skeletal health and disease. *Eur J Endocrinol* **168**(6):R95-103.

76. Honma M, Ikebuchi Y, Kariya Y, Suzuki H 2014 Regulatory mechanisms of RANKL presentation to osteoclast precursors. *Curr Osteoporos Rep* **12**(1):115-120.
77. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R 2012 Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. *Nat Rev Drug Discov* **11**(5):401-419.
78. Sutton EE, Riche DM 2012 Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. *Ann Pharmacother* **46**(7-8):1000-1009.
79. Shimizu-Ishiura M, Kawana F, Sasaki T 2002 Osteoprotegerin administration reduces femoral bone loss in ovariectomized mice via impairment of osteoclast structure and function. *J Electron Microsc (Tokyo)* **51**(5):315-325.
80. Greenfield EM 2012 Anabolic effects of intermittent PTH on osteoblasts. *Current molecular pharmacology* **5**(2):127-134.
81. Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H 2009 Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. *J Bone Miner Res* **24**(7):1194-1205.
82. Kaiser J 2003 Hormesis. Sipping from a poisoned chalice. *Science* **302**(5644):376-379.
83. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-Hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H 2013 Pathogenic conversion of Foxp3 T cells into TH17 cells in autoimmune arthritis. *Nat Med* **20**(1):62-68.
84. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA 2009 Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. *Nat Immunol* **10**(9):1000-1007.
85. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA 2013 Self-antigen-Driven Activation Induces Instability of Regulatory T Cells during an Inflammatory Autoimmune Response. *Immunity* **39**(5):949-962.

86. Mayer CT, Berod L, Sparwasser T 2012 Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. *Front Immunol* **3**:183.
87. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q 2010 Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. *Blood* **116**(2):210-217.
88. Kimmel DB 1996 Animal models for in vivo experimentation in osteoporosis research. *Osteoporosis* **2**:29-47.

FIGURE LEGENDS:

Figure 1: T_CREG are induced by activated osteoclasts: A. RANKL treatment increases

T_CREG levels in bone marrow in FoxP3^{eGFP} reporter mice: The numbers of FoxP3⁺ CD8 T-cells (T_CREG) that are found in the bone marrow and spleen are plotted (y-axis) as a function of RANKL dose (x-axis), 50 h after first dose. The cells were gated on the lymphocytes (by forward and side-scatter), then on double positive CD45 and CD3 T-cells and finally on CD8, GFP double positive cells for quantitation. **B. RANKL treatment activates osteoclasts:** Serum

CTX levels increase in response to low-dose (0.125 mg/kg) and high-dose (1 mg/kg) RANKL.

C. T_CREG are induced in the bone marrow: To test for T_CREG induction by RANKL activated osteoclasts, congenically marked (Thy 1.2) GFP negative CD8 T-cells (see panel D for FACS plots) were adoptively transferred into Thy 1.1 OT-I Rag^{-/-} mice. In the absence of RANKL treatment very low level of conversion was observed after three days. Low-dose (0.125 mg/kg) RANKL robustly induced T_CREG; T_CREG induction was measured 50 h after RANKL treatment and 3 days after T-cell transfer. Cells were isolated from tibia and femurs (bone marrow) for FACS analysis. The induction required active osteoclasts as no induction of T_CREG was observed in mice pre-treated (two-weeks prior to T-cell transfer) with Zoledronic acid (ZA). **D.**

Representative FACS plots are shown for panel C. The results represent mean ± standard deviation (error bars) from 4 experiments (n = 4 mice/group/experiment). P values were calculated using Mann-Whitney test; * = P < 0.05; ** = P < 0.01; **** = P < 1x10⁻⁴; and NS = not statistically significant.

Figure 2: T_CREG levels are not changed in ovariectomized mice but the T_CREG can suppress osteoclast activity *in vitro*: A. No change in T_CREG levels despite increased osteoclast

activity: The abundance of T_CREG in sham-operated mice was similar to the levels found in ovariectomized (OVX) mice. **B. T_CREG from ovariectomized mice can suppress bone**

resorption: T_CREG purified by magnetic beads from the bone marrow of sham-operated (Sham), ovariectomized (OVX) and WT (C57BL/6J) mice treated with low-dose RANKL (WT+ldRNL; 0.125 mg/kg) were tested in a matrix dissolution assay. To assess the levels of repression, the results are expressed as normalized area resorbed relative to wells with osteoclasts with no T_CREG added (None). All T_CREG suppressed bone resorption by osteoclasts indicating that the T_CREG are

functional. The results represent mean \pm standard deviation (error bars) from 2 experiments (n = 3 mice/group/experiment). P values were calculated using Mann-Whitney test; * = P < 0.05 and NS = not statistically significant.

Figure 3: The pro-inflammatory cytokines IL-17A and TNF α suppress T_{REG} induction by osteoclasts: **A. T_{REG} induction by osteoclasts in the presence of IL-17:** T_{REG} were induced *in vitro* using OT-I CD8 T-cells co-cultured with bone marrow cells-derived osteoclasts, pulsed with SIINFEKL ovalbumin peptide. T_{REG} induction was observed in OT-I T-cells in the absence of (0 ng/ml) but significantly reduced in the presence of 10 ng/ml IL-17A. **B. T_{REG} induction by osteoclasts in the presence of TNF α :** TNF α also reduced T_{REG} induction in a dose dependent manner. Similar levels of suppression of T_{REG} induction was observed at 50 or 100 ng/ml RANKL each dose of TNF α indicating that the ratio of RANKL to TNF α is not critical. ANOVA analysis to determine the variation due to TNF α and RANKL concentration indicates that TNF α accounted for 85.5% of the total variance (P < 0.0001) and RANKL accounted for 0.65% of the total variance (P < 0.001). The interaction term accounted for remaining 9.3% of the total variance indicating that TNF α had a strong effect at each concentration of RANKL tested. The results represent mean \pm standard deviation (error bars) from 4 experiments (n = 4 wells / group / experiment). P values were calculated using Mann-Whitney test; **** = P < 1x10⁻⁴ and ** = P < 0.01 relative to no (0 ng/ml of) TNF α .

Figure 4: CD200 but not CD80/CD86 are used by osteoclasts as costimulatory signal to T-cells: **A. Osteoclasts from CD80/CD86^{-/-} can induce T_{REG}:** Osteoclasts derived from bone marrow cells of CD80/CD86 double knockout mice were capable of inducing T_{REG} to a similar extent to wild-type (WT) derived osteoclasts. **B. T_{REG} produce similar levels of cytokines when primed by WT or double-knockout osteoclasts:** The levels of cytokines produced by T_{REG} induced by WT osteoclast and CD80/CD86 double knockouts were indistinguishable. Taken together, these results indicate that CD80/CD86 are not used for costimulation of CD8 T-cells by osteoclasts. **C. Blockade by CD200 decreases T_{REG} induction:** Soluble CD200-Fc added to OT-I CD8 T-cells prior to coculturing with osteoclasts blocked FoxP3 induction. **D. CD200 expression is not altered by TNF α or IL-17:** CD200 expression is not detected in osteoclast precursors but is expressed in mature osteoclast. Recombinant murine TNF α (20 ng/ml) or IL-17A (10 ng/ml) had no effect on CD200 expression in mature osteoclasts. The

results represent mean \pm standard deviation (error bars) from 4 experiments (n = 4 mice/group/experiment). P values were calculated using Mann-Whitney test; **** = $P < 1 \times 10^{-4}$ and ** $P < 0.01$.

Figure 5: Notch signaling by ligand DLL4, expressed on osteoclasts, induces T_CREG *in vitro*:

A. Inhibition of γ -secretase blocks T_CREG induction by osteoclasts: DAPT, a γ -secretase inhibitor, dissolved in DMSO was used to test the role of Notch signaling in the induction of T_CREG. 10 μ M DAPT completely inhibited T_CREG induction. Data represents four independent experiments with four wells/group/experiment. **B. Notch ligands expressed in mature osteoclasts:** RT-PCR was used to determine which Notch ligands are expressed on osteoclasts and CD8 T-cells. Of the six Notch ligands encoded in the mouse genome, mature osteoclasts express Jagged (Jag)-1, Jag-2, Delta-like (DLL)-1 and DLL4. The CD8 T-cells also express Jag2 and DLL-1. **C. RANKL induces DLL4 expression while IL-17 and TNF α represses it:** Of these four Notch ligands expressed in mature osteoclasts, only DLL4 was absent in the osteoclast precursors by qPCR. DLL4 expression was repressed in mature osteoclasts in the presence of recombinant murine 20 ng/ml TNF α and 10 ng/ml IL-17A. **D. Blockade of DLL4 inhibits T_CREG induction *in vivo*:** Soluble DLL4-Fc, but not a control IgG1-Fc, administered 2 hours prior to RANKL administration blocked T_CREG induction *in vivo*. The design of this *in vivo* induction experiment was identical to that used in Fig. 1B and 1C. **E. DLL4 acts as switch in response to RANKL levels:** Addition of RANKL increased the expression of DLL4 even in the presence of 20 ng/ml TNF α . **F. RANKL addition in presence of TNF α restores T_CREG induction by osteoclasts:** Concomitant with the expression of DLL4, addition of RANKL also restores induction of T_CREG in the presence of 10 (solid line) or 20 ng/ml (dashed line) TNF α . Statistical comparisons (P values) are relative to 25 ng/ml RANKL and 20 ng/ml TNF α treatment. ANOVA indicates that 90.7% of the variance was accounted for by RANKL treatment ($P < 0.0001$), and 1.83% of the variance by TNF α treatment ($P = 0.0002$). The interaction term accounted for 1.6% of the variance ($P = 0.0147$) indicating that the effect of RANKL was dominant at both concentrations of TNF α tested. The results represent mean \pm standard deviation (error bars) from three independent experiments with 4 wells / group / experiment. P values were calculated using Mann-Whitney test; **** = $P < 1 \times 10^{-4}$; *** = $P < 0.001$; ** $P < 0.01$ and NS = not statistically significant.

Figure 6: Low-dose RANKL induces functional T_{CREG} in ovariectomized mice: A.

Induction of T_{CREG} in the bone marrow of ovariectomized mice in response to low-dose

RANKL: Intraperitoneal administration of low dose RANKL (RL; 0.125 mg/kg) induced T_{CREG} in the bone marrow of ovariectomized mice. Representative FACS contour plots are shown on the first and second panel and the distribution (N= 8 mice per group) is shown in the third panel.

B. T_{CREG} induction in ovariectomized mice suppresses bone resorption by lowering osteoclast numbers in ovariectomized mice:

Relative to sham-operated (S) mice the serum CTX levels increased in ovariectomized mice, but decreased in groups of ovariectomized mice treated with low-dose RANKL (RL), Zoledronate (ZA) or treated by adoptive-transfer of *ex vivo* generated T_{CREG} (T_{CREG}). The decrease in serum CTX by T_{CREG} is mediated by decreasing numbers of osteoclasts per area of bone surface (N.OC/BS; center panel) and is reflected in the decrease of bone surface occupied by osteoclast surface (OC.S/BS; right panel). Representative images are shown below.

C. T_{CREG} induction in ovariectomized mice increases bone

volume and bone density: The tibias of groups of mice were evaluated by μ CT to determine ratio of bone volume to total volume (BV/TV; left panel) and bone mineral density (BMD; right panel). Representative images from proximal tibia are shown.

D. T_{CREG} induction in ovariectomized mice increases bone formation rate:

Low-dose RANKL treatment also increased mineral apposition rate (left panel) and bone formation rate (right panel) to a greater extent than Zoledronate and *ex vivo* generated T_{CREG}. Representative images from the double-labeled femur (calcein green and alizarin red) from each group are shown. Arrows are shown to emphasize the distance between dyes.


E. T_{CREG} induced by low-dose RANKL treated mice have immunosuppressive function:

Low-dose RANKL and adoptive transfer of *ex vivo* generated T_{CREG} decreased proinflammatory T_{EFF} (gated on lymphocyte side-scatter/forward-scatter, then CD3 and CD45 double positive, and CD3 and CD44 double positive) cells in the bone marrow. The results represent mean \pm standard deviation (error bars) from 4 experiments (n = 4 mice/group/experiment). P values were calculated using Mann-Whitney test; **** = P < 1x10⁻⁴; *** = P < 1x10⁻³, ** = P < 0.01 * = P < 0.05 and NS = not statistically significant.

Figure 7: The anabolic effect of low-dose RANKL treatment in ovariectomized mice is mediated through CD8 T-cells:


To confirm that decrease in bone erosion and effector T-cell levels is mediated via T_{CREG}, β 2M^{-/-} mice lacking CD8 T-cells, were sham-operated (S; n=6), ovariectomized (OVX; n=6) and ovariectomized then treated with low-dose RANKL (ldRL =

0.125 mg/kg; n=6). In some experiments mice are also treated with high-dose RANKL (hdRL = 1 mg/kg). **A. Low-dose RANKL treatment of ovariectomized mice lacking CD8 T-cells does not decrease T_{EFF}:** Ovariectomy of $\beta 2M^{-/-}$ mice increased effector T-cells (CD3⁺ and CD44⁺) relative to sham-operated (indicated by S). However, unlike treatment of CD8 T-cell-replete mice, no decrease in levels of effector T-cells was observed due to low-dose RANKL (ldRL) treatment in $\beta 2M^{-/-}$ mice. **B. Low-dose RANKL treatment of ovariectomized mice lacking CD8 T-cells does not decrease bone resorption:** Bone resorption levels, as assayed by serum CTX, increase in CD8 T-cell ($\beta 2M^{-/-}$) deficient ovariectomized mice relative to sham-operated mice. A modest increase in serum CTX is observed in ovariectomized $\beta 2M^{-/-}$ mice treated with low-dose RANKL. **C. Low-dose RANKL treatment of ovariectomized mice lacking CD8 T-cells does not increase bone volume or bone density:** Ovariectomy leads to significant levels of bone loss relative in $\beta 2M^{-/-}$ mice. Low-dose RANKL leads to further decrease in bone volume (BV/TV) and bone mineral density (BMD) in $\beta 2M^{-/-}$ mice, indicating that CD8 T-cells in WT mice protect against bone loss. **D.** Representative μ CT renderings for panels C and E. **E. Low-dose RANKL treatment of ovariectomized mice is bone anabolic but not in mice lacking CD8 T-cells:** In WT mice low-dose RANKL is anti-resorptive in ovariectomized mice but promotes bone loss in estrogen-replete mice. Treatment with high-dose RANKL (1mg/kg; n= 6 mice per group) leads to bone resorption in both estrogen-deficient and replete mice. In CD8 T-cell-deficient mice low dose RANKL leads to bone loss in both estrogen-replete (Sham) and ovariectomized (OVX) mice. Percentage of bone volume lost (or gained; BV/TV) relative to reference state (untreated sham surgery or ovariectomy - indicated by horizontal dashed line) is also given. The results represent mean \pm standard deviation (error bars). P values were calculated using Mann-Whitney test; *** = P < 0.001 and * = P < 0.05. **E. A model of the negative feedback loop between osteoclast-induced Tc_{REG}:** In ovariectomized mice increased levels of proinflammatory cytokines TNF α and IL-17 suppress DLL4 expression needed for Tc_{REG} induction (left panel). In the absence of Tc_{REG} and in the presence of the proinflammatory cytokine the activated osteoclasts have increased bone resorption leading to osteoporosis. Treatment with low-dose RANKL (right panel) reverses the repression of DLL4 in ovariectomized mice leading to induction of Tc_{REG} by osteoclasts to engage the negative feedback loop. Induction of Tc_{REG} not only limits osteoclastogenesis but also reduced the proinflammatory effector T-cells. The reduction in T_{EFF} leads to increased bone formation rate.




Buchwald et al. Fig. 1

A.




B.




Buchwald et al. Fig. 2

A.



B.



Buchwald et al. Fig. 3





Fig. 4



Buchwald et al. Fig. 5




Fig. 6




Fig. 7 Buchwald et al.